Recently, a study including two cohorts of 626 and 929 patients with MPN observed that patients treated with JAK1/2 inhibitors developed aggressive lymphomas (n = 6) 15–16-fold more frequently than patients not exposed to these treatments [35]. Here, JAK1 is linked to myeloproliferative disorder.